Medpace Holdings, Inc. $MEDP Shares Purchased by Renaissance Group LLC

Renaissance Group LLC lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 30.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,349 shares of the company’s stock after purchasing an additional 4,259 shares during the period. Renaissance Group LLC’s holdings in Medpace were worth $5,759,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. raised its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Brooklyn Investment Group lifted its holdings in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Medpace during the 1st quarter worth $60,000. IFP Advisors Inc increased its position in shares of Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after acquiring an additional 134 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its position in Medpace by 5,075.0% in the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after purchasing an additional 203 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MEDP. Jefferies Financial Group boosted their price target on shares of Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research note on Tuesday, September 9th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. BMO Capital Markets assumed coverage on Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective on the stock. Mizuho upped their price target on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. Finally, TD Cowen boosted their target price on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $487.18.

Medpace Stock Up 0.8%

Shares of MEDP stock opened at $590.18 on Wednesday. The stock has a market cap of $16.62 billion, a P/E ratio of 41.27, a P/E/G ratio of 2.67 and a beta of 1.42. The business has a fifty day simple moving average of $543.35 and a 200-day simple moving average of $428.47. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the prior year, the firm earned $3.01 earnings per share. The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Buying and Selling

In other news, General Counsel Stephen P. Ewald sold 15,230 shares of Medpace stock in a transaction on Monday, October 27th. The stock was sold at an average price of $598.85, for a total value of $9,120,485.50. Following the completion of the sale, the general counsel owned 13,343 shares of the company’s stock, valued at $7,990,455.55. The trade was a 53.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total value of $12,808,476.98. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at $8,934,900. This trade represents a 58.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 170,255 shares of company stock worth $96,157,774 in the last 90 days. 20.30% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.